Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.33 USD
+0.15 (1.34%)
Updated May 14, 2024 04:00 PM ET
After-Market: $11.32 -0.01 (-0.09%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Roivant Sciences Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 61 | 55 | 24 | NA |
Cost Of Goods | NA | 13 | 9 | 2 | NA |
Gross Profit | NA | 48 | 46 | 22 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 1,223 | 1,398 | 1,093 | 0 |
Income After Depreciation & Amortization | 0 | -1,175 | -1,352 | -1,071 | 0 |
Non-Operating Income | NA | -22 | 428 | 172 | NA |
Interest Expense | NA | 28 | 0 | 0 | NA |
Pretax Income | NA | -1,225 | -924 | -899 | NA |
Income Taxes | NA | 5 | 0 | 2 | NA |
Minority Interest | NA | -106 | -79 | -91 | NA |
Investment Gains/Losses | NA | 0 | 0 | 0 | NA |
Other Income/Charges | NA | 0 | 0 | 0 | NA |
Income From Cont. Operations | NA | -1,230 | -924 | -900 | NA |
Extras & Discontinued Operations | NA | 115 | 0 | 0 | NA |
Net Income (GAAP) | NA | -1,009 | -845 | -809 | NA |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -1,156 | -1,352 | -1,071 | 0 |
Depreciation & Amortization (Cash Flow) | NA | 19 | 0 | 0 | NA |
Income After Depreciation & Amortization | 0 | -1,175 | -1,352 | -1,071 | 0 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 712.79 | 669.75 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.58 | -1.26 | NA | NA |
Diluted Net EPS (GAAP) | NA | -1.42 | -1.26 | NA | NA |
Fiscal Year end for Roivant Sciences Ltd falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 37.14 | 37.10 | 21.62 | 27.38 |
Cost Of Goods | NA | 3.67 | 3.27 | 4.21 | 4.18 |
Gross Profit | NA | 33.47 | 33.84 | 17.41 | 23.20 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | -5,027.41 | 310.29 | 293.82 | 257.37 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 5,060.88 | -276.45 | -276.41 | -234.17 |
Non-Operating Income | NA | 46.90 | -41.66 | -40.77 | 50.73 |
Interest Expense | NA | 9.44 | 9.25 | 8.91 | 27.97 |
Pretax Income | NA | 5,098.34 | -327.36 | -326.09 | -179.22 |
Income Taxes | NA | 25.67 | 3.76 | 1.75 | -3.79 |
Minority Interest | NA | -23.52 | -26.79 | -36.03 | -27.24 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 5,072.67 | -331.12 | -327.85 | -175.42 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 114.56 |
Net Income (GAAP) | NA | 5,096.18 | -304.33 | -291.82 | -33.62 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 844.46 | 770.23 | 759.27 | 742.54 |
Diluted EPS Before Non-Recurring Items | NA | -0.26 | -0.33 | -0.38 | -0.20 |
Diluted Net EPS (GAAP) | NA | 6.03 | -0.40 | -0.38 | -0.03 |